NNC0487-0111 for Obesity

(AMAZE 4 Trial)

This trial tests the effectiveness and safety of a new treatment, NNC0487-0111, for individuals who are overweight or have obesity and obstructive sleep apnea, a condition where breathing stops and starts during sleep. Participants will receive weekly injections of either the new treatment or a placebo, a substance with no active medicine, to evaluate the treatment's efficacy. The trial is ideal for those diagnosed with moderate-to-severe sleep apnea who are already using a positive airway pressure device. As a Phase 3 trial, this study is the final step before potential FDA approval, allowing participants to contribute to the development of a promising new treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using certain diabetes medications like GLP-1 receptor agonists or similar treatments.

Research has shown that NNC0487-0111 has promising safety results from earlier studies involving individuals with excess body weight and some with type 2 diabetes. Reports indicate that the treatment is well-tolerated, with most participants not experiencing major side effects.

In one study, most side effects were mild and manageable without stopping the treatment. NNC0487-0111 is now undergoing advanced clinical trials, indicating it has already demonstrated good safety in earlier stages.

Unlike the standard treatments for obesity, which often include oral medications or lifestyle changes, NNC0487-0111 is administered subcutaneously, meaning it's injected under the skin once a week. This unique delivery method could potentially enhance its effectiveness and convenience for patients. Additionally, NNC0487-0111 is designed to work alongside a reduced-calorie diet and increased physical activity, potentially offering a more integrated approach to weight management. Researchers are excited about its potential to provide a new option for patients who struggle with existing treatments.

Research shows that NNC0487-0111, also known as amycretin, may help treat obesity. In this trial, participants will receive either NNC0487-0111 or a placebo. Studies have found that people taking amycretin lost significantly more weight than those taking a placebo (a pill with no active ingredient). Specifically, one study showed participants lost an average of 13.1% of their body weight, while those on the placebo lost only 1.2%. Another study demonstrated weight loss of up to 22% over several weeks. Amycretin combines two substances that reduce appetite and support weight loss. Overall, the evidence suggests that NNC0487-0111 could effectively help people with obesity lose weight.⁶⁷⁸⁹¹⁰